Details
Stereochemistry | ACHIRAL |
Molecular Formula | C7H10N4O2S |
Molecular Weight | 214.245 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(=N)NS(=O)(=O)C1=CC=C(N)C=C1
InChI
InChIKey=BRBKOPJOKNSWSG-UHFFFAOYSA-N
InChI=1S/C7H10N4O2S/c8-5-1-3-6(4-2-5)14(12,13)11-7(9)10/h1-4H,8H2,(H4,9,10,11)
Molecular Formula | C7H10N4O2S |
Molecular Weight | 214.245 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including
http://jama.jamanetwork.com/article.aspx?articleid=254816
https://www.mpbio.com/product.php?pid=02102984&country=195
Curator's Comment: description was created based on several sources, including
http://jama.jamanetwork.com/article.aspx?articleid=254816
https://www.mpbio.com/product.php?pid=02102984&country=195
Sulfaguanidine is used to treat the gastrointestinal infections particularly bacillary dysentery. Sulfaguanidine is a sulfonamide antibiotic that blocks the synthesis of dihydrofolic acid by inhibiting the enzyme dihydropteroate synthase in bacteria. Sulfonamides are active against Gram positive bacteria and Gram negative bacteria.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: bacterial dihydropteroate synthase |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | Unknown Approved UseUnknown |
|||
Curative | ENTEROPATHYL Approved UseAcute or chronic diarrhea caused by sulfaguanidine-sensitive organisms. |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.41 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3820055/ |
2.5 mg/kg single, oral dose: 2.5 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
SULFAGUANIDINE plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.04 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3820055/ |
2.5 mg/kg single, oral dose: 2.5 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
SULFAGUANIDINE plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3820055/ |
2.5 mg/kg single, oral dose: 2.5 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
SULFAGUANIDINE plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
4 g 6 times / day multiple, oral Dose: 4 g, 6 times / day Route: oral Route: multiple Dose: 4 g, 6 times / day Sources: |
unhealthy, 32 n = 1 Health Status: unhealthy Condition: diarrhea Age Group: 32 Sex: M Population Size: 1 Sources: |
Other AEs: Anuria... |
0.05 g/kg 6 times / day multiple, oral Dose: 0.05 g/kg, 6 times / day Route: oral Route: multiple Dose: 0.05 g/kg, 6 times / day Sources: |
unhealthy, 45 n = 1 Health Status: unhealthy Condition: diarrhea Age Group: 45 Sex: F Population Size: 1 Sources: |
Disc. AE: Headache, Nausea... AEs leading to discontinuation/dose reduction: Headache Sources: Nausea |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Anuria | 4 g 6 times / day multiple, oral Dose: 4 g, 6 times / day Route: oral Route: multiple Dose: 4 g, 6 times / day Sources: |
unhealthy, 32 n = 1 Health Status: unhealthy Condition: diarrhea Age Group: 32 Sex: M Population Size: 1 Sources: |
|
Headache | Disc. AE | 0.05 g/kg 6 times / day multiple, oral Dose: 0.05 g/kg, 6 times / day Route: oral Route: multiple Dose: 0.05 g/kg, 6 times / day Sources: |
unhealthy, 45 n = 1 Health Status: unhealthy Condition: diarrhea Age Group: 45 Sex: F Population Size: 1 Sources: |
Nausea | Disc. AE | 0.05 g/kg 6 times / day multiple, oral Dose: 0.05 g/kg, 6 times / day Route: oral Route: multiple Dose: 0.05 g/kg, 6 times / day Sources: |
unhealthy, 45 n = 1 Health Status: unhealthy Condition: diarrhea Age Group: 45 Sex: F Population Size: 1 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
In vitro model to assess effect of antimicrobial agents on Encephalitozoon cuniculi. | 1994 Oct |
|
Monodrug efficacies of sulfonamides in prophylaxis for Pneumocystis carinii pneumonia. | 1996 Apr |
|
Efficacy of 101 antimicrobials and other agents on the development of Cryptosporidium parvum in vitro. | 1996 Dec |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21434161
0.08 mg/kg per day; 7-14 days (daily dose: 2-3 mg)
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15061593
Sulfaguanidine at dose of 2500 ppm proved to be most toxic against A. corymbifera causing 56.39 percent inhibition in the mycelial growth, while the same dose could not be found much effective against other test fungi.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:21:16 GMT 2023
by
admin
on
Fri Dec 15 15:21:16 GMT 2023
|
Record UNII |
15XQ8043FN
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29739
Created by
admin on Fri Dec 15 15:21:17 GMT 2023 , Edited by admin on Fri Dec 15 15:21:17 GMT 2023
|
||
|
WHO-ATC |
A07AB03
Created by
admin on Fri Dec 15 15:21:17 GMT 2023 , Edited by admin on Fri Dec 15 15:21:17 GMT 2023
|
||
|
WHO-VATC |
QA07AB03
Created by
admin on Fri Dec 15 15:21:17 GMT 2023 , Edited by admin on Fri Dec 15 15:21:17 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID1023609
Created by
admin on Fri Dec 15 15:21:17 GMT 2023 , Edited by admin on Fri Dec 15 15:21:17 GMT 2023
|
PRIMARY | |||
|
D013414
Created by
admin on Fri Dec 15 15:21:17 GMT 2023 , Edited by admin on Fri Dec 15 15:21:17 GMT 2023
|
PRIMARY | |||
|
57-67-0
Created by
admin on Fri Dec 15 15:21:17 GMT 2023 , Edited by admin on Fri Dec 15 15:21:17 GMT 2023
|
PRIMARY | |||
|
5324
Created by
admin on Fri Dec 15 15:21:17 GMT 2023 , Edited by admin on Fri Dec 15 15:21:17 GMT 2023
|
PRIMARY | |||
|
SULFAGUANIDINE
Created by
admin on Fri Dec 15 15:21:17 GMT 2023 , Edited by admin on Fri Dec 15 15:21:17 GMT 2023
|
PRIMARY | |||
|
94621
Created by
admin on Fri Dec 15 15:21:17 GMT 2023 , Edited by admin on Fri Dec 15 15:21:17 GMT 2023
|
PRIMARY | |||
|
C76977
Created by
admin on Fri Dec 15 15:21:17 GMT 2023 , Edited by admin on Fri Dec 15 15:21:17 GMT 2023
|
PRIMARY | |||
|
DB13726
Created by
admin on Fri Dec 15 15:21:17 GMT 2023 , Edited by admin on Fri Dec 15 15:21:17 GMT 2023
|
PRIMARY | |||
|
CHEMBL338802
Created by
admin on Fri Dec 15 15:21:17 GMT 2023 , Edited by admin on Fri Dec 15 15:21:17 GMT 2023
|
PRIMARY | |||
|
200-345-9
Created by
admin on Fri Dec 15 15:21:17 GMT 2023 , Edited by admin on Fri Dec 15 15:21:17 GMT 2023
|
PRIMARY | |||
|
14041
Created by
admin on Fri Dec 15 15:21:17 GMT 2023 , Edited by admin on Fri Dec 15 15:21:17 GMT 2023
|
PRIMARY | |||
|
2505
Created by
admin on Fri Dec 15 15:21:17 GMT 2023 , Edited by admin on Fri Dec 15 15:21:17 GMT 2023
|
PRIMARY | |||
|
SUB10703MIG
Created by
admin on Fri Dec 15 15:21:17 GMT 2023 , Edited by admin on Fri Dec 15 15:21:17 GMT 2023
|
PRIMARY | |||
|
423
Created by
admin on Fri Dec 15 15:21:17 GMT 2023 , Edited by admin on Fri Dec 15 15:21:17 GMT 2023
|
PRIMARY | |||
|
10174
Created by
admin on Fri Dec 15 15:21:17 GMT 2023 , Edited by admin on Fri Dec 15 15:21:17 GMT 2023
|
PRIMARY | RxNorm | ||
|
m10310
Created by
admin on Fri Dec 15 15:21:17 GMT 2023 , Edited by admin on Fri Dec 15 15:21:17 GMT 2023
|
PRIMARY | Merck Index | ||
|
100000083248
Created by
admin on Fri Dec 15 15:21:17 GMT 2023 , Edited by admin on Fri Dec 15 15:21:17 GMT 2023
|
PRIMARY | |||
|
15XQ8043FN
Created by
admin on Fri Dec 15 15:21:17 GMT 2023 , Edited by admin on Fri Dec 15 15:21:17 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |